<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980694</url>
  </required_header>
  <id_info>
    <org_study_id>UQ01</org_study_id>
    <nct_id>NCT00980694</nct_id>
  </id_info>
  <brief_title>Bioavailability of Ubiquinol in Huntington Disease</brief_title>
  <official_title>Bioavailability of Ubiquinol in Huntington Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaneka Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack
      of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ)
      is a marketed nutritional supplement that may prove useful in HD because it increases cell
      energy and combats free radicals.

      Most studies of CoQ have looked at only one formulation of CoQ (&quot;ubiquinone&quot;) in HD. The
      purpose of the study is to find out if people that switch from the common formulation of CoQ
      (&quot;ubiquinone&quot;) to a different formulation (&quot;ubiquinol&quot;) have higher levels of CoQ in their
      blood after taking the same dose. The investigators also want to find out if this different
      formulation is tolerable for individuals with HD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum coenzyme Q10 levels</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Ubiquinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to 600 mg per day, oral capsules for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ubiquinol</intervention_name>
    <description>up to 600 mg per day, oral capsules for 8 weeks</description>
    <arm_group_label>Ubiquinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have manifest Huntington disease

          -  Be 18 years of age or older

          -  Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline
             visit

          -  Be on a steady dose of all concomitant medications for at least 30 days prior to the
             baseline visit

        Exclusion Criteria:

          -  Have a history of intolerability of sensitivity to CoQ

          -  Have an unstable medical or psychiatric illness

          -  Be pregnant or breastfeeding; women of childbearing age must use reliable
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Kieburtz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Karl Kieburtz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ubiquinol</keyword>
  <keyword>coenzyme Q10</keyword>
  <keyword>Huntington disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

